Arcus sets the hopes for Tigit in lung cancer
As biopharma awaits Roche’s pivotal Skyscraper-01 data Arcus gives its investors some more tea leaves to read.
Bristol needs to get fresh
Move over Amgen – Bristol Myers Squibb now looks like the big biopharma group most in need of revitalisation.
Despite slow progress, Boehringer keeps faith in oncology
The group highlights its ambitions in cancer again, but is at least two years away from launching a new product.
Go or no go? Bristol's first-in-class hopes
April should mark the approval of some of the biggest drugs of 2022, including Alnylam's vutrisiran, while TG will hope to be spared pain at the PI3K adcom.
